Temperature-controlled logistics company Cryoport Inc (NASDAQ: CYRX) has been selected by DiscGenics to provide logistics support to its multicenter, first-in-human study. The study aims to evaluate the safety and preliminary efficacy of IDCT, DiscGenics’ allogeneic injectable cell therapy, in patients with single-level, symptomatic lumbar intervertebral disc degeneration.
Cryoport’s temperature-controlled logistics support services will include outbound logistics for DiscGenics’ Clinical Phase 1/2 trial of IDCT to clinics in both the United States, and eventually Japan.
“Degenerative disc disease can cause immense suffering for patients, yet current treatment options are limited,” said Flagg Flanagan, chief executive officer and chairman of the board of directors for DiscGenics. “We are excited to commence clinical evaluation of IDCT, which utilizes proprietary therapeutic progenitor cells derived from adult human disc tissue to offer a non-surgical, potentially regenerative and cost-effective solution for the treatment of patients with mild to moderate degenerative disc disease.
“Using Cryoport’s premium cold chain logistics solutions not only ensures we maintain superior quality assurance of our clinical trial materials when shipping both domestically and internationally, but also minimizes the risk of costly delays and clinical product loss during shipping as we progress through the trial,” said Flanagan.
Jerrell Shelton, CEO of Cryoport, said, “DiscGenics is engaged in conducting clinical trials for their groundbreaking regenerative therapy for patients with chronic low-back pain, and we are proud to be selected to ship their biological product and injection kits to clinical sites in the United States and Japan. Cryoport’s reputation for reliability and safety were critical for DiscGenics when deciding to entrust its valuable cell therapies to a logistics partner.”
For more information, visit www.cryoport.com.
